开云app官网登录入口网页版-官方正版

#血管性水肿#

27篇内容 | 1409人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1447076, encodeId=355c144e07602, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=NEJM：Donidalorsen可降低遗传性血管性水肿发作风险改善患者生活质量, objectType=article, longId=301024, objectId=986030102477, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=986030102477, replyNumber=0, likeNumber=81, createdTime=2022-03-19, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=986030102477, moduleTitle=NEJM：Donidalorsen可降低遗传性血管性水肿发作风险改善患者生活质量, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=986030102477)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447075, encodeId=6b3e144e07576, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=Lancet：Garadacimab可有效预防C1酯酶抑制剂缺乏性遗传性血管性水肿患者的水肿发作, objectType=article, longId=299975, objectId=14d32999e546, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14d32999e546, replyNumber=0, likeNumber=98, createdTime=2022-03-04, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14d32999e546, moduleTitle=Lancet：Garadacimab可有效预防C1酯酶抑制剂缺乏性遗传性血管性水肿患者的水肿发作, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=14d32999e546)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447074, encodeId=7af8144e07425, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=JACC：缓激肽受体B2基因附近的常见变异可增加ACEi相关血管性水肿风险, objectType=article, longId=215846, objectId=377e2158469e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=377e2158469e, replyNumber=0, likeNumber=66, createdTime=2021-08-18, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=377e2158469e, moduleTitle=JACC：缓激肽受体B2基因附近的常见变异可增加ACEi相关血管性水肿风险, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=377e2158469e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447073, encodeId=ca3c144e0732a, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=武田针对急性遗传性血管性水肿发作的治疗药物飞泽优®获批，保障中国HAE患者生命安全, objectType=article, longId=209352, objectId=229a20935293, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=229a20935293, replyNumber=0, likeNumber=75, createdTime=2021-04-04, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=229a20935293, moduleTitle=武田针对急性遗传性血管性水肿发作的治疗药物飞泽优®获批，保障中国HAE患者生命安全, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=229a20935293)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447072, encodeId=eae2144e0724b, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=浙江有关遗传性血管性水肿调研出炉聚焦罕见病患者困境, objectType=article, longId=208022, objectId=3b102080221a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b102080221a, replyNumber=0, likeNumber=63, createdTime=2021-03-08, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b102080221a, moduleTitle=浙江有关遗传性血管性水肿调研出炉聚焦罕见病患者困境, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3b102080221a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447071, encodeId=a050144e07139, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=AAAAI 2021：PHA121治疗遗传性血管性水肿（HAE）取得积极结果, objectType=article, longId=207428, objectId=a3c020e428da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3c020e428da, replyNumber=0, likeNumber=87, createdTime=2021-02-23, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3c020e428da, moduleTitle=AAAAI 2021：PHA121治疗遗传性血管性水肿（HAE）取得积极结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a3c020e428da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447070, encodeId=aadd144e07031, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=日本厚生劳动省（MHLW）批准ORLADEYO（贝罗司他）用于遗传性血管性水肿的预防性治疗, objectType=article, longId=206188, objectId=8ad420618870, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ad420618870, replyNumber=0, likeNumber=50, createdTime=2021-01-26, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ad420618870, moduleTitle=日本厚生劳动省（MHLW）批准ORLADEYO（贝罗司他）用于遗传性血管性水肿的预防性治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8ad420618870)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447069, encodeId=3095144e069bf, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=NEJM：反义疗法治疗遗传性血管性水肿，初见有效性端倪, objectType=article, longId=200190, objectId=fc1e200190f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc1e200190f9, replyNumber=0, likeNumber=65, createdTime=2020-09-05, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc1e200190f9, moduleTitle=NEJM：反义疗法治疗遗传性血管性水肿，初见有效性端倪, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fc1e200190f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447068, encodeId=71d8144e06845, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=NEJM：t-PA输注后血管性水肿-病例报道, objectType=article, longId=196079, objectId=c19e1960e995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c19e1960e995, replyNumber=0, likeNumber=75, createdTime=2020-06-19, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c19e1960e995, moduleTitle=NEJM：t-PA输注后血管性水肿-病例报道, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c19e1960e995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447067, encodeId=28d3144e0677a, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=EAACI 2020：长期临床数据证实Berotralstat可稳定持久地减少遗传性血管性水肿患者的发作, objectType=article, longId=195487, objectId=d55819548e54, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d55819548e54, replyNumber=0, likeNumber=103, createdTime=2020-06-10, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d55819548e54, moduleTitle=EAACI 2020：长期临床数据证实Berotralstat可稳定持久地减少遗传性血管性水肿患者的发作, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d55819548e54)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447066, encodeId=29bb144e066df, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=纵隔小细胞癌致上腔静脉综合征误诊为血管性水肿 1 例, objectType=article, longId=190972, objectId=d9381909e2ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9381909e2ab, replyNumber=0, likeNumber=76, createdTime=2020-03-29, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9381909e2ab, moduleTitle=纵隔小细胞癌致上腔静脉综合征误诊为血管性水肿 1 例, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d9381909e2ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447065, encodeId=04c5144e0654c, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=TAKHZYRO（lanadelumab注射液）获得加拿大药物专家委员会的积极推荐，用于常规预防遗传性血管性水肿（HAE）发作, objectType=article, longId=183553, objectId=65371835530b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65371835530b, replyNumber=0, likeNumber=60, createdTime=2019-11-26, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65371835530b, moduleTitle=TAKHZYRO（lanadelumab注射液）获得加拿大药物专家委员会的积极推荐，用于常规预防遗传性血管性水肿（HAE）发作, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=65371835530b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447064, encodeId=b519144e064ab, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=遗传性血管性水肿患者眼科手术麻醉一例, objectType=article, longId=182907, objectId=c75e18290e7f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c75e18290e7f, replyNumber=0, likeNumber=69, createdTime=2019-11-14, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c75e18290e7f, moduleTitle=遗传性血管性水肿患者眼科手术麻醉一例, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c75e18290e7f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447063, encodeId=b715144e063f3, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=Stroke：脑卒中患者溶栓治疗中血管性水肿, objectType=article, longId=168205, objectId=45181682053e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45181682053e, replyNumber=0, likeNumber=66, createdTime=2019-06-13, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45181682053e, moduleTitle=Stroke：脑卒中患者溶栓治疗中血管性水肿, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=45181682053e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447062, encodeId=7bc9144e062a6, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=ZENITH-1试验：口服BCX7353治疗急性遗传性血管性水肿发作具有显著效果, objectType=article, longId=161119, objectId=4774161119ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4774161119ce, replyNumber=0, likeNumber=81, createdTime=2019-02-27, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4774161119ce, moduleTitle=ZENITH-1试验：口服BCX7353治疗急性遗传性血管性水肿发作具有显著效果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4774161119ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447061, encodeId=0b08144e061e9, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=Blood：C1抑制剂正常的遗传性血管性水肿的发病机制, objectType=article, longId=158174, objectId=082c1581e414, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=082c1581e414, replyNumber=0, likeNumber=74, createdTime=2019-01-17, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=082c1581e414, moduleTitle=Blood：C1抑制剂正常的遗传性血管性水肿的发病机制, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=082c1581e414)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447060, encodeId=6294144e06064, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=CHMP支持Shire旗下Takhzyro用于预防遗传性血管性水肿的发作, objectType=article, longId=151515, objectId=6107151515af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6107151515af, replyNumber=0, likeNumber=81, createdTime=2018-10-23, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6107151515af, moduleTitle=CHMP支持Shire旗下Takhzyro用于预防遗传性血管性水肿的发作, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6107151515af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447059, encodeId=11f0144e059bc, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=FDA拒绝将Pharming公司的Ruconest用于预防遗传性血管性水肿, objectType=article, longId=149491, objectId=131f14949190, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=131f14949190, replyNumber=0, likeNumber=62, createdTime=2018-09-25, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=131f14949190, moduleTitle=FDA拒绝将Pharming公司的Ruconest用于预防遗传性血管性水肿, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=131f14949190)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447058, encodeId=0239144e05890, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=NEJM：口服血浆激肽释放酶抑制剂预防遗传性血管性水肿, objectType=article, longId=145226, objectId=f633145226de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f633145226de, replyNumber=0, likeNumber=77, createdTime=2018-07-28, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f633145226de, moduleTitle=NEJM：口服血浆激肽释放酶抑制剂预防遗传性血管性水肿, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f633145226de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447057, encodeId=705a144e057dc, content=<a href='/topic/show?id=ccf5896426d' target=_blank style='color:#2F92EE;'>#血管性水肿#</a>, objectTitle=BioCryst启动BCX7353对遗传性血管性水肿患者的长期安全性试验, objectType=article, longId=131025, objectId=db211310250f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db211310250f, replyNumber=0, likeNumber=67, createdTime=2018-03-02, rootId=0, userName=guoyibin, userId=9c785304850, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db211310250f, moduleTitle=BioCryst启动BCX7353对遗传性血管性水肿患者的长期安全性试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=db211310250f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

血管性水肿

2020-05-29

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

NEJM：Donidalorsen可降低遗传性血管性水肿发作风险改善患者生活质量

2022-03-19

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

Lancet：Garadacimab可有效预防C1酯酶抑制剂缺乏性遗传性血管性水肿患者的水肿发作

2022-03-04

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

JACC：缓激肽受体B2基因附近的常见变异可增加ACEi相关血管性水肿风险

2021-08-18

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

武田针对急性遗传性血管性水肿发作的治疗药物飞泽优®获批，保障中国HAE患者生命安全

2021-04-04

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

浙江有关遗传性血管性水肿调研出炉聚焦罕见病患者困境

2021-03-08

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

AAAAI 2021：PHA121治疗遗传性血管性水肿（HAE）取得积极结果

2021-02-23

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

日本厚生劳动省（MHLW）批准ORLADEYO（贝罗司他）用于遗传性血管性水肿的预防性治疗

2021-01-26

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

NEJM：反义疗法治疗遗传性血管性水肿，初见有效性端倪

2020-09-05

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

NEJM：t-PA输注后血管性水肿-病例报道

2020-06-19

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

EAACI 2020：长期临床数据证实Berotralstat可稳定持久地减少遗传性血管性水肿患者的发作

2020-06-10

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

纵隔小细胞癌致上腔静脉综合征误诊为血管性水肿 1 例

2020-03-29

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

TAKHZYRO（lanadelumab注射液）获得加拿大药物专家委员会的积极推荐，用于常规预防遗传性血管性水肿（HAE）发作

2019-11-26

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

遗传性血管性水肿患者眼科手术麻醉一例

2019-11-14

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

Stroke：脑卒中患者溶栓治疗中血管性水肿

2019-06-13

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

ZENITH-1试验：口服BCX7353治疗急性遗传性血管性水肿发作具有显著效果

2019-02-27

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

Blood：C1抑制剂正常的遗传性血管性水肿的发病机制

2019-01-17

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

CHMP支持Shire旗下Takhzyro用于预防遗传性血管性水肿的发作

2018-10-23

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

FDA拒绝将Pharming公司的Ruconest用于预防遗传性血管性水肿

2018-09-25

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

NEJM：口服血浆激肽释放酶抑制剂预防遗传性血管性水肿

2018-07-28

guoyibin (审核中...)

前往app查看评论内容

#血管性水肿#

BioCryst启动BCX7353对遗传性血管性水肿患者的长期安全性试验

2018-03-02

科室
- - 订阅+
  - 更多科室
工具
服务